Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

BioCardia Inc

Company price
None USD 0.00(0%)
Last update at 2024-09-11T10:45:44.227826Z
Market Cap
0.00M

Momentum Score

…

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. BioCardia, Inc. is based in Sunnyvale, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.01
Low
1.06
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.47M
Revenue Per Share
0.02
Gross Profit TTM
0.00M
Debt / Equity
-0.82
ROE
-703.62%
Net Debt
0.21M
ROCE
1929.63%
Diluted EPS TTM
-3.20

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -11.91M -12.62M -15.00M -14.71M -13.99M
Net income -11.91M -12.62M -15.01M -14.82M -13.87M
Selling general administrative 4.42M 5.09M 5.86M 6.00M 5.76M
Gross profit -10.55M 1.01M 0.14M 0.35M 0.11M
Reconciled depreciation 0.08M 0.06M 0.07M 0.11M 0.09M
Ebit -11.98M -12.63M -15.53M -14.21M -14.10M
Ebitda -11.90M -12.56M -15.44M -14.02M -13.90M
Depreciation and amortization 0.08M 0.07M 0.09M 0.20M 0.20M
Non operating income net other - - 0.53M - -
Operating income -11.90M -12.63M -15.53M -14.21M -14.10M
Other operating expenses 13.25M 13.64M 15.67M 14.92M 14.73M
Interest expense 0.01M 0.01M 0.00M 0.11M 0.12M
Interest income - 0.01M 0.02M 0.03M 0.12M
Net interest income - 0.01M 0.02M -0.03M 0.12M
Income tax expense 0.01M -0.00M 0.00M 0.11M -0.12M
Total revenue 1.35M 1.01M 0.14M 0.71M 0.62M
Total operating expenses 13.25M 13.64M 15.67M 14.56M 14.21M
Cost of revenue 11.90M 0.00M 0.00M 0.36M 0.52M
Total other income expense net -0.01M 0.01M 0.53M -0.50M 0.12M
Net income from continuing ops -11.91M -12.62M -15.00M -14.71M -13.99M
Net income applicable to common shares - - -15.00M -14.71M -13.99M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 2.99M 9.79M 15.72M 23.42M 7.68M
Other current assets 0.29M 0.50M 0.46M 1.25M 0.64M
Total liab 4.59M 4.90M 5.34M 4.25M 5.31M
Total stockholder equity -1.60M 4.89M 10.38M 19.18M 2.37M
Other current liab 1.82M 1.62M 1.44M 1.50M 1.83M
Common stock 0.02M 0.02M 0.02M 0.02M 0.01M
Capital stock 0.02M 0.02M 0.02M 0.02M 0.01M
Retained earnings -152.18M -140.60M -128.70M -116.07M -101.07M
Other assets - - - 0.62M 0.05M
Cash 1.10M 7.36M 12.87M 21.41M 5.58M
Total current liabilities 3.61M 3.58M 3.71M 4.25M 4.00M
Current deferred revenue 0.56M 0.96M 1.53M 1.39M 0.73M
Net debt 0.21M -5.73M -11.00M -20.79M -4.44M
Short term debt 0.33M 0.32M 0.24M 0.61M 0.53M
Short long term debt total 1.31M 1.63M 1.87M 0.61M 1.14M
Other stockholder equity 150.55M 145.48M 139.06M 135.23M 103.43M
Property plant equipment - - - 0.14M 1.25M
Total current assets 1.46M 7.86M 13.48M 22.66M 6.38M
Net tangible assets - - - 19.18M -
Net receivables 0.06M 0.20M 0.15M 0.85M 0.15M
Inventory - -0.20M - -0.85M 0.00M
Accounts payable 0.89M 0.68M 0.51M 0.75M 0.91M
Common stock total equity - - - 0.02M 0.01M
Retained earnings total equity - - - -116.07M -
Non currrent assets other 0.17M 0.17M 0.17M 0.05M 0.05M
Non current assets total 1.53M 1.93M 2.24M 0.77M 1.30M
Capital lease obligations 1.31M 1.63M 1.87M 0.61M 1.14M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.07M -0.12M -0.03M -0.15M -0.07M
Change to liabilities - - 0.62M - -
Total cashflows from investing activities - - -0.03M -0.15M -0.07M
Net borrowings - - 0.51M - -
Total cash from financing activities 5.12M 1.95M 28.21M 9.82M 3.80M
Net income -11.91M -12.62M -15.00M -14.71M -13.99M
Change in cash -5.51M -8.54M 15.82M 0.23M -7.33M
Begin period cash flow 12.87M 21.41M 5.58M 5.36M 12.69M
End period cash flow 7.36M 12.87M 21.41M 5.58M 5.36M
Total cash from operating activities -10.56M -10.37M -12.36M -9.45M -11.07M
Issuance of capital stock 5.54M 2.00M 30.50M 10.45M 3.80M
Depreciation 0.08M 0.06M 0.07M 0.11M 0.09M
Change to inventory - 0.51M 0.00M 0.14M 0.05M
Change to account receivables -0.05M 0.09M -0.09M 0.13M -0.18M
Sale purchase of stock - - 27.86M -5.58M -5.36M
Other cashflows from financing activities -0.42M -0.05M -2.29M -0.63M 0.00M
Change to netincome - - 2.45M - -
Capital expenditures 0.07M 0.12M 0.03M 0.15M 0.07M
Change receivables - - -0.70M - -
Cash flows other operating - - 0.21M - -
Cash and cash equivalents changes - - 15.82M - -
Change in working capital -0.21M 0.52M -0.36M 1.41M 0.06M
Stock based compensation 1.18M 1.66M 2.95M 2.72M 2.77M
Other non cash items 0.29M 0.02M 0.00M 0.11M 7.37M
Free cash flow -10.63M -10.48M -12.39M -9.59M -11.13M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12

Profile*

BioCardia Inc

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. BioCardia, Inc. is based in Sunnyvale, California.

320 Soquel Way, Sunnyvale, CA, United States, 94085

650 226 0120

16

Name Title Year Born
Dr. Peter A. Altman Ph.D. CEO, President & Director 1967
Mr. David McClung Chief Financial Officer 1963
Mr. Edward M. Gillis Senior Vice President of Devices 1962
Dr. Sujith Shetty MBBS Chief Medical Officer and VP of Clinical & Regulatory NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…